Except for TMEM176A, only three genes (ANXA3, ARG1 and HP) showed consistently > 10% change in risk in all three comparisons (all LC cases vs. FalsePos, NSCLC cases vs. FalsePos and late-stage LC cases vs. FalsePos), though these were statistically significant only for all LC cases versus FalsePos without smoking adjustment (Supplementary Table S5). This evidence concerns the gene HP and laryngotracheoesophageal cleft.